

# BMJ Open Randomised controlled trial of *Lactobacillus rhamnosus* (LGG) versus placebo in children presenting to the emergency department with acute gastroenteritis: the PECARN probiotic study protocol

David Schnadower,<sup>1</sup> Phillip I Tarr,<sup>2</sup> T Charles Casper,<sup>3</sup> Marc H Gorelick,<sup>4</sup> Michael J Dean,<sup>3</sup> Karen J O'Connell,<sup>5</sup> Prashant Mahajan,<sup>6,7</sup> Thomas H Chun,<sup>8</sup> Seema R Bhatt,<sup>9</sup> Cindy G Roskind,<sup>10</sup> Elizabeth C Powell,<sup>11</sup> Alexander J Rogers,<sup>7</sup> Cheryl Vance,<sup>12</sup> Robert E Sapien,<sup>13</sup> Feng Gao,<sup>14</sup> Stephen B Freedman<sup>15</sup>

**To cite:** Schnadower D, Tarr PI, Casper TC, *et al.* Randomised controlled trial of *Lactobacillus rhamnosus* (LGG) versus placebo in children presenting to the emergency department with acute gastroenteritis: the PECARN probiotic study protocol. *BMJ Open* 2017;**7**:e018115. doi:10.1136/bmjopen-2017-018115

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-018115>).

Received 7 June 2017  
Revised 22 August 2017  
Accepted 24 August 2017



CrossMark

For numbered affiliations see end of article.

## Correspondence to

Dr David Schnadower;  
schnadower\_d@wustl.edu

## ABSTRACT

**Introduction** Acute gastroenteritis (AGE) is a common and burdensome condition that affects millions of children worldwide each year. Currently available strategies are limited to symptomatic management, treatment and prevention of dehydration and infection control; no disease-modifying interventions exist. Probiotics, defined as live microorganisms beneficial to the host, have shown promise in improving AGE outcomes, but existing studies have sufficient limitations such that the use of probiotics cannot currently be recommended with confidence. Here we present the methods of a large, rigorous, randomised, double-blind placebo-controlled study to assess the effectiveness and side effect profile of *Lactobacillus rhamnosus* GG (LGG) (ATCC 53103) in children with AGE. **Methods and analysis** The study is being conducted in 10 US paediatric emergency departments (EDs) within the federally funded Pediatric Emergency Care Applied Research Network, in accordance with current SPIRIT and CONSORT statement recommendations. We will randomise 970 children presenting to participating EDs with AGE to either 5 days of treatment with LGG (10<sup>10</sup> colony-forming unit twice a day) or placebo between July 2014 to December 2017. The main outcome is the occurrence of moderate-to-severe disease over time, as defined by the Modified Vesikari Scale. We also record adverse events and side effects related to the intervention. We will conduct intention-to-treat analyses and use an enrichment design to restore the statistical power in case the presence of a subpopulation with a substantially low treatment effect is identified.

**Ethics and dissemination** Institutional review board approval has been obtained at all sites, and data and material use agreements have been established between the participating sites. The results of the trial will be published in peer-reviewed journals. A deidentified public data set will be made available after the completion of all study procedures.

**Trial registration number** NCT01773967.

## Strengths and limitations of this study

- This is a large multicentre randomised, double-blind, placebo-controlled trial in a diverse and geographically varied US population of children with gastroenteritis.
- We perform independent laboratory product testing to assess probiotic viability, dosing and purity.
- We use a statistical enrichment design to restore the statistical power if a subpopulation with a substantially low treatment effect is identified.
- Outcome is based on parental report of symptoms rather than direct observation
- Enrolment is limited to day and evening hours only, when research personnel is available.

## INTRODUCTION

Acute gastroenteritis (AGE) is a leading cause of malnutrition and death worldwide.<sup>1</sup> Though rarely fatal in North America, ~48 million people in the USA contract AGE, and 128 000 are hospitalised annually.<sup>2</sup> Although the incidence of rotavirus infection in the USA has decreased since the introduction of the vaccine in 2006,<sup>3</sup> norovirus is now the leading cause of medically attended paediatric AGE in this country.<sup>4</sup> Unfortunately, current interventions are limited to rehydration, symptomatic management and supportive care and prevention of severe dehydration and secondary infections.<sup>5–8</sup>

Probiotics, defined as live microorganisms that when administered in adequate amounts are intended to confer health benefits on the recipients,<sup>9 10</sup> represent a novel approach to improved management of paediatric AGE.

Probiotics are generally considered to be safe, easily administered and hypothesised to modulate disease processes.<sup>11</sup> Meta-analyses of various probiotic products have reported reduced symptom durations in children with AGE who have been treated with these agents. However, the studies included in these analyses have had important methodological limitations such as small sample sizes, lack of probiotic quality control, outcomes that are of minimal relevance to patients and their families and unclear randomisation, allocation concealment and blinding and attrition biases.<sup>12–15</sup> Remarkably, few studies of probiotics have evaluated outpatients, a group that represents the preponderance of AGE episodes in the USA,<sup>16–18</sup> and only one small study has evaluated probiotics in children with AGE presenting to a US emergency department (ED), where no benefit was demonstrated.<sup>19</sup>

Given the lack of adequate efficacy and safety evidence, most guidelines do not endorse the use of probiotics in paediatric AGE.<sup>12 15 20–23</sup> However, the European Society of Pediatric Gastroenterology, Hepatology and Nutrition has offered a ‘strong’ recommendation in support of specific probiotics to treat previously healthy children with AGE, despite their acknowledgement of the ‘low quality of the evidence’.<sup>24</sup> Furthermore, probiotic manufacturers aggressively market probiotics citing health claims that have not been supported by rigorous research,<sup>25–28</sup> and the US market for digestive health enzymes, prebiotics and probiotics was estimated at US\$495 million in 2015 and was expected to grow at an annual rate of 13%.<sup>29</sup> Despite these concerns about their value, and issues surrounding safety and regulatory oversight,<sup>30–32</sup> parents of patients with AGE often administer probiotics to their children without guidance from medical professionals.<sup>9 22</sup> We are therefore concerned that the consumption of probiotics is increasing without adequate evidence to support their use, which underscores the necessity of conducting a definitive trial. There is strong consensus that an adequately powered randomised controlled trial (RCT), using a well-defined probiotic agent and comprehensive and clinically sensible validated outcome measures in a clinically relevant patient population will provide much needed clarity to this field.<sup>12 15 33–35</sup>

Here, we report on the methodology of a double-blind placebo-controlled pragmatic RCT (ClinicalTrials.gov: NCT01773967), using *Lactobacillus rhamnosus* GG (LGG) (ATCC 53103), the most available and studied probiotic in the USA as the intervention.<sup>36 37</sup> The research is supported by funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD R01HD071915) and is conducted under the oversight of the Food and Drug Administration (FDA investigational new drug 12371), in 10 US EDs within the federally funded Pediatric Emergency Care Applied Research Network (PECARN). The objectives of this double-blind placebo-controlled RCT are to (1) determine if, compared with placebo, LGG reduces the severity of AGE episodes in children aged 3–48 months

presenting to an ED with AGE and (2) determine the safety and side effect profile of LGG in children with AGE.

We hypothesise that (1) in children with AGE, LGG will be associated with a clinically meaningful decrease in the proportion of children suffering from a moderate-to-severe episode of AGE defined by a validated Modified Vesikari Scale (MVS) score of  $\geq 9$ , compared with placebo, and (2) LGG will not be associated with serious adverse events and will have a similar rate of side effects (eg, bloating and fever) compared with placebo-treated children.

## METHODS AND ANALYSIS

### Overview

This is a double-blind, 10-centre, paediatric ED-based RCT conducted by the PECARN. Children aged 91 days to <48 months who present to a participating ED between July 2014 to December 2017 will be assessed for eligibility, approached for informed consent and randomised to receive 5 days of a probiotic (LGG  $10^{10}$  colony-forming unit (CFU) twice a day) or placebo. Physicians, patients, study personnel and outcome assessors are blinded to the intervention. LGG and the placebo are administered twice daily. The study will be conducted and reported according to the most recent SPIRIT and CONSORT statement recommendations.<sup>38–40</sup>

### Setting

Patients are being recruited at 10 US paediatric EDs in PECARN (St. Louis Children’s Hospital (St. Louis, Missouri, lead site), Lurie Children’s Hospital (Chicago, Illinois), Cincinnati Children’s Hospital Medical Center (Cincinnati, Ohio), Children’s Hospital of New York-Presbyterian (New York City, New York), Hasbro Children’s Hospital (Providence, Rhode Island), Children’s Hospital of Michigan (Detroit, Michigan), UC Davis Medical Center (Sacramento, California), CS Mott Children’s Hospital (Ann Arbor, Michigan) and the University of New Mexico Children’s Hospital (Albuquerque, New Mexico). Each centre has a strong research infrastructure and successfully participated in multicentre ED-based trials. Together the sites serve a large and diverse patient population. PECARN, the umbrella collaborative network, is the first federally funded paediatric research network in the USA and has an extensive record of successful multicentre research.<sup>41</sup> The PECARN Data Coordinating Center (DCC), based at the University of Utah, is responsible for data management and data analysis. An independent Data Safety Monitoring Board (DSMB) composed of specialists in paediatric infectious diseases, paediatric gastroenterology, paediatric emergency medicine and biostatistics was formed to review enrolment, study procedures, case report form completion, data quality, loss to follow-up, drop-in rate and interim safety and efficacy results.

### Inclusion criteria and rationale

1. *Presence of diarrhoea*: defined as  $\geq 3$  watery stools in the 24 hours prior to assessment,<sup>42</sup> with or without vomiting (vomiting alone, which may be the sentinel sign of AGE, could also represent non-infectious illnesses and is therefore not a sufficient criterion to qualify for eligibility).
2. *Duration of vomiting or diarrhea  $\leq 7$  days*: as we are focusing on acute diarrhoea, which typically is of less than 7 days' duration.<sup>18</sup> It is unclear if probiotics are useful in the early or later stages of AGE,<sup>19</sup> our enrichment design will allow for adaptive randomisation if a particular group is more likely to benefit from treatment.
3. *Age 91 days–<48 months*: AGE severity and frequency are greatest among young children,<sup>43</sup> including those who visit North American EDs.<sup>17 44 45</sup>
4. *Symptoms consistent with AGE per treating physician*: this is to ensure that only children with a presumptive diagnosis of AGE are included in the study.

### Exclusion criteria and rationale

1. *Presence of an indwelling vascular access line or structural heart disease*: potential bacteraemia risk with intervention.<sup>46</sup>
2. *Receiving immunosuppressive therapy, or history of immunodeficiency*: potential bacteraemia risk with intervention.<sup>47</sup>
3. *Haematochezia*: (studies show little efficacy of probiotics in children with bacterial AGE, and visible blood in the stool is a marker for such pathogens).<sup>48 49</sup>
4. *Chronic gastrointestinal problems (eg, short gut syndrome and inflammatory bowel disease)*: diarrhoea in such children is more likely to be related to non-infectious causes.
5. *Critically ill patients or patients admitted to the intensive care unit*: these patients are at risk of invasive disease, and their ability to comply with an oral intervention might be limited.
6. *Household member with an indwelling vascular access line, on immunosuppressive therapy or with a known immunodeficiency*: risk for invasive disease if there is intrahousehold dissemination of the LGG (note that this exclusion does not extend to household contacts who use a short course ( $< 7$  days) of oral steroids or are using inhaled steroids).
7. *Bilious emesis*: might indicate a diagnosis other than AGE.
8. *Probiotic use (supplement) in the preceding 2 weeks*: confounding risk; consumption of foods containing probiotics will not result in exclusion as they are ubiquitous.
9. *Previously enrolled in this trial*: to ensure that the observations are independent.
10. *Daily telephone follow-up not possible while symptomatic*: avoid loss to follow-up because of travel plans or language barrier.
11. *Allergy to Lactobacillus or microcrystalline cellulose (MCC)*: contents of capsule and placebo.

12. *Allergy to beta-lactam antibiotics, erythromycin and clindamycin*: these antibiotics might be used in the event of LGG extraintestinal dissemination.

Children taking antibiotics will *not* be excluded because probiotics remain viable when given concomitantly with antibiotics, and the survival of the active bacterial strains is not diminished.<sup>50</sup>

### Participant allocation

#### Sequence generation

The PECARN DCC produced randomisation lists, stratified by study site and duration of symptoms, using random number-generating software. The lists were sent to the central pharmacy (Cincinnati Children's Hospital Medical Center) that prepares consecutively numbered study kits according to the randomisation schedule. These are sent by courier to the clinical sites where they are stored in the research support pharmacies.

#### Allocation concealment

Randomisation was performed at the DCC using random block sizes with a 1:1 allocation ratio. Stratifying by clinical site ensures that variations (eg, site-specific practice patterns and gastrointestinal pathogens) are comparably distributed across treatment arms. Only the DCC retains the randomisation code. Unblinding can be requested by treating medical personnel in case of an emergency requiring such information.

### Implementation

Potentially eligible patients are identified by triage nurses at each site who contact the research assistant (RA). The RA then (1) screens patients for eligibility, (2) maintains a log of all screened patients, (3) discusses the details of the study with the caregivers of all eligible children, (4) obtains consent, (5) enrolls children, (6) consecutively assigns a patient identification number, (7) randomises the patient (using a web-based system: [www.randomize.net](http://www.randomize.net)), (8) collects baseline demographic clinical variables and (9) in conjunction with the treating physician, completes data collection forms.

### Intervention

#### LGG and placebo capsule contents

LGG, ATCC 53103 is supplied in a gelatin capsule containing  $10^{10}$  CFU LGG. Each LGG capsule contains 75 mg of LGG and 250 mg of MCC, an inert ingredient. The placebo capsules contain only MCC (325 mg). Each capsule is wrapped in double foil to protect it against light, air and moisture. Blister packs are labelled with the lot number. LGG and placebo capsules and powder are identical in appearance, taste, texture and odour. LGG capsules and placebo capsules have active Drug Master Files at the FDA (BB-MF 213 668 and MF2 13 646, respectively). The dose and duration of therapy are based on the currently available evidence.<sup>51–63</sup>

#### ED intervention

The patient's nurse administers the first dose of either LGG ( $10^{10}$  CFU/dose) or placebo on site by sprinkling

the capsule's contents into 30 mL of room temperature, non-carbonated liquid. The RA provides caregivers with verbal and written instructions regarding (1) study drug administration; (2) completion of study forms; (3) what and how much fluid to drink; (4) criteria for seeing a healthcare practitioner or returning to the ED; and (5) standardised AGE discharge instructions and letter to their primary care provider explaining the study. All other aspects of medical care will be at the discretion of the treating physician.

#### Home intervention

All patients consume one capsule of LGG or placebo, based on randomisation, every 12 hours for 5 days ( $10^{10}$  CFU twice daily  $\times$  5 days, for a total of nine home doses). Patients receive the medication at meal time, mixed with 30 mL of a room temperature non-carbonated liquid and ingested immediately to optimise probiotic viability. Oral fluid therapy is encouraged according to established guidelines.<sup>21</sup> The study protocol is continued in the subset of children (estimated <5%) who are hospitalised.<sup>18</sup> Also, caregivers are provided with a letter to share with their primary care provider (in case they visit their provider during the course of the study). The letter describes the study and the care plan, and it includes site investigator's contact information and the importance of adhering to the study protocol. Patients may withdraw from the study at any time based on their or their physician's discretion; however, efforts will be made to proceed with safety follow-up, and the subjects will be included in the intention-to-treat (ITT) analysis.

#### Stool sample testing

Stool samples (swab or bulk stool, as available) from all enrolled children are collected, frozen and sent to Washington University – St. Louis Children's Hospital Virology Laboratory and tested with multiplex PCR using the Luminex xTag Gastrointestinal Pathogen Panel (Luminex, Austin, Texas, USA), which identifies the following organisms (and specific bacterial loci): viruses: norovirus (GI and GII), adenovirus F 40/41 and rotavirus (A); bacteria: *Escherichia coli* O157, enterotoxigenic *E. coli* (*lt/st*), Shiga toxin-producing *E. coli* (*stx1/stx2*), *Vibrio cholerae*, *Shigella* spp., *Salmonella* spp., *Campylobacter* spp., *Yersinia enterocolitica* and *Clostridium difficile* (*tcd A/B*); and parasites: *Cryptosporidium* spp., *Giardia* spp. and *Entamoeba histolytica*.

In addition, St. Louis Children's Hospital and the New Mexico Children's Hospital collect and freeze bulk stool specimens in the acute phase (within 24 hours of presentation) and following resolution (14 days after presentation) using a home stool collection protocol. The protocol consists of providing the family with a specimen collection kit, gel packs and an insulated envelope at enrolment. When the specimen is ready for collection, a courier retrieves the specimen and cool pack at the patient's home and delivers it to a logistics collection centre. The stools are frozen on receipt in St. Louis and

Albuquerque, and then stored in the Tarr Laboratory at Washington University at  $-80^{\circ}\text{C}$  for future testing.

#### Data Collection

All caregivers receive discharge instructions that include information on tasks required following discharge along with a diary to record daily symptoms and all information requested during the telephone calls or electronic surveys, including side effects (see supplemental file: follow-up surveys). Follow-up occurs daily until symptoms resolve or 5 days, whichever occurs later, and again at 14 days and 1, 3, 6, 9 and 12 months following enrolment. Data collected daily and at day 14 follow-up are used to measure efficacy and short-term safety outcomes. Long-term follow-up data (1 month onwards) are used to assess long-term adverse events, unanticipated medical encounters and development of new chronic illnesses in accordance to FDA guidelines (Guidance for Industry and Investigators: Safety Reporting and Requirements for INDs and BA/BE Studies).<sup>64</sup> We use a standardised script and data collection forms to obtain follow-up information by telephone or via email survey. Follow-up procedures are centralised at the lead site. We also perform chart reviews to verify data regarding revisits, intravenous hydration, hospitalisation and microbiology testing using each centre's medical record database. Personal data will be handled in compliance of the Health Insurance Portability and Accountability Act. Data are entered in to encrypted and secure central databases managed by the DCC at the University of Utah, where state-of-the-art equipment and procedures ensure data quality and security.

#### Compliance

We assess patient compliance with therapy on day 5 and collect final data on day 14. To maximise compliance, caregivers are reminded of the importance and method of administering the probiotic/placebo. A similar scheme has been used in our previous studies.<sup>18 65–67</sup>

#### Probiotic quality control/independent testing

We test samples of all batches of probiotic product at an independent laboratory twice a year until expiration date to ensure adequate bacterial counts. In order to maximise bacterial viability, probiotic products are kept refrigerated at research pharmacies between  $0^{\circ}\text{C}$  and  $4^{\circ}\text{C}$ . Shipping and storage logs are retained.

#### Study monitoring

The DCC coordinated site (in-person and remote) monitoring as well as pharmacy monitoring at the beginning and once during the study. The monitor has provided each site with a written report, and sites have been required to respond to and resolve deficiencies. Sponsoring and regulatory agency monitoring is at the discretion of such agencies.

#### Outcome measures

The primary outcome to measure efficacy is the presence of moderate-to-severe AGE, as defined by a total

**Table 1** Modified Vesikari Score

Points	0	1	2	3
Diarrhoea duration	0	1–96 hours	97–120 hours	≥121 hours
Max no. of diarrhoeal stools/24 hours	0	1–3	4–5	≥6
Vomiting duration	0	1–24 hours	25–48 hours	≥49 hours
Max no. of vomiting episodes/24 hours	0	1	2–4	≥5
Max recorded fever	≤37°C	37.1–38.4°C	38.5–38.9°C	≥39°C
Unscheduled healthcare visit	0	–	Primary care	Emergency department
Treatment	None	Rehydration	Hospital admission	–

postenrolment MVS score  $\geq 9$  during the 2-week follow-up period (table 1). This scale has been validated in our patient populations.<sup>18 45</sup> Each of the seven items in the scale is tabulated individually (maximum of 20 points); the sum of these individual variables represents the total MVS score. At the time of randomisation (time 0), a pre-enrolment MVS score is assigned based on symptoms prior to presentation. This score serves as a covariate in a secondary analysis of the primary outcome. The post-enrolment MVS score used to determine the presence/absence of the primary study outcome, is based only on symptoms that occur between time 0 (ie, randomisation) and the conclusion of the study period (ie, day 14). The post-enrolment score is calculated only once, on day 14. At that time, each of the seven variables are assigned a score for the entire study period (time 0 to day 14). Each variable is scored in 1 of 3 methods: (1) worst 24 hours period—maximal number of episodes of vomiting in a 24-hour period, maximal number of episodes of diarrhoea in a 24-hour period and maximal temperature); (2) total duration of symptoms, including the number of days on which any gastroenteritis-related symptom occurred. For scoring purposes, the episode of AGE concludes after absence of symptoms for 24 hours; and (3) occurrence of an outcome—treatment and subsequent healthcare utilisation. A score of  $\geq 9$  defines moderate-to-severe disease because on the original score, severe disease was defined as  $\geq 11$ <sup>68–72</sup> and moderate as  $\geq 9$ .<sup>73</sup> In our derivation and validation pilot studies,<sup>18 45</sup> construct validity was demonstrated and validated by using scores of  $\geq 9$  to define moderate and  $\geq 11$  to define severe disease. These cut-points were associated with significant increases in other measures of disease severity such as degree of dehydration, likelihood of admission and daycare and parental work absenteeism.<sup>18 45</sup>

#### Main safety outcome

The main safety outcome is the occurrence of extraintestinal infection by the administered probiotic agent—LGG. Based on previous human experience with LGG in healthy volunteers, pregnant women, neonates and children with AGE, we do not anticipate that any extraintestinal infections will occur. Adverse event analysis will follow

FDA guidelines for assessment of attribution, toxicity grading scale and criteria for patient withdrawal. Per FDA recommendations, we conducted an interim safety analysis after the first 80 patients, including 40 less than 1 year of age, had completed their 1-month follow-up.

#### Secondary outcomes (efficacy)

Secondary outcomes include the following: (1) diarrhoea duration: time from treatment initiation until the appearance of the last watery stool as reported during daily phone conversations, (2) vomiting duration, (3) return visits for unscheduled care to a healthcare provider related to vomiting, diarrhoea, dehydration, fever or fluid refusal, within 2 weeks of the index visit. We will not include scheduled visits (eg, reassessment, vaccinations and unrelated issues). This outcome is important because  $>50\%$  of children with AGE have a follow-up office visit,<sup>16</sup> 8%–18% require an ED visit and 5%–8% are hospitalised.<sup>16</sup> (4) Days of daycare missed by subjects, (5) days of work missed by caregivers and (6) household transmission rate: a household census is obtained at the time of enrolment, and we obtain information about incident household symptoms during the telephone follow-up calls. Secondary transmission is an integral feature of AGE, and households are relevant and well-established study units.<sup>74–76</sup>

#### Secondary outcomes (safety)

The secondary safety outcome is the presence of potential side effects such as bloating, gas, intestinal rumbling, diarrhoea, blood in stool, abdominal pain, abdominal cramps, nausea, vomiting, loss of appetite, abnormal taste, heartburn, constipation, skin rash, fever, nasal congestion, sore throat, cough, headache, malaise, muscle aches and chills. We acknowledge, however, that some toxicities will be difficult to distinguish from abdominal symptoms related to the AGE, and only at the time of data analysis will we be able to determine if these signs and symptoms differ between the groups (ie, by comparing the differences in occurrence between the active and placebo groups). The study physicians complete the appropriate form for all adverse events identified during the scheduled or unscheduled phone calls. During long-term follow-up telephone calls (ie, those occurring after

14 days postenrolment), we inquire about unexpected events obligating medical attention and new onset of chronic disorders, especially those involving the digestive system.

#### Data analysis and sample size

All analyses will be undertaken by the ITT principle, except for side effects, which will use the ‘as-treated’ principle (compare the subjects based on the treatment regimen that they received). Patients who withdraw, drop out or crossover will be followed and included in the ITT analysis. All statistical tests of hypotheses will be two sided. For cases where information needed to derive the primary outcome is incomplete, we will use multiple imputation methods. The proportion of children with moderate-to-severe disease (ie, MVS  $\geq 9$ ), the primary outcome will be analysed by comparing proportions using a Mantel-Haenszel test, stratified by participating centre and duration of symptoms prior to presentation. Significance for this primary outcome measure will be set at 0.05. Secondary analyses of the primary outcome will use logistic regression methods to adjust for covariates (eg, age, pre-enrolment MVS, hydration assessment and need for hospitalisation at index visit). We will also analyse the outcome using MVS as a continuous variable through a stratified Wilcoxon rank-sum test and compare the results with the primary analysis.

The overall significance level for statistical tests on the secondary outcomes will be set at 0.05. Holm’s method will be used to adjust for multiple comparisons.<sup>77</sup> The continuous variables of durations of (1) diarrhoea and (2) vomiting will be measured in hours and analysed with a Van Elteren test<sup>78</sup> and stratified by clinical centre and duration of symptoms. Similarly, the number of days (3) the child is absent from daycare and (4) the caregiver is absent from work will be analysed with a Van Elteren test, stratified by clinical centre and duration of symptoms. Dichotomous outcomes to be evaluated include ED AGE-related revisits, intravenous rehydration and hospitalisation. These six outcomes will be jointly assessed for significance using Holm’s method. Additional analyses involving these outcomes will include linear and logistic regression models that adjust for possible effects of baseline characteristics. The proportions of children experiencing (5) an unscheduled healthcare visit or (6) any potential adverse effect, as reported by the caregivers, will be compared between groups using the Mantel-Haenszel test, stratified by site and duration of symptoms. The analysis will evaluate the presence/absence of prespecified side effects, as an aggregate outcome variable. A per-protocol analysis will be conducted to provide additional insight as non-compliance may result in an underestimation of the benefits of probiotics in the ITT analysis.<sup>79</sup>

#### Power analysis

The primary analysis will be performed on a binary outcome: development of moderate-to-severe disease. The power of this analysis depends on the proportion of

**Table 2** Power analysis.

Outcome control	Outcome intervention	% Difference	Power
0.30	0.21	9	0.76
0.30	0.20	10	0.85
0.25	0.15	10	0.90
0.25	0.16	9	0.82
0.25	0.17	8	0.72
0.20	0.10	10	0.95
0.20	0.12	8	0.81
0.20	0.13	7	0.69

Highlighted area corresponds to stated assumptions in the text.

patients with moderate-to-severe disease in each group considered. Data collected as part of our pilot evaluations of the MVS in 729 children aged 3–48 months demonstrated that when using the ED visit as time 0, 25% of eligible children had scores consistent with moderate-to-severe disease following discharge.<sup>18 45</sup> This is a lower rate than previous reports of diarrhoea in paediatric EDs<sup>69 70</sup> and in the community<sup>68 71 73</sup> but is attributed to our exclusion of symptoms that existed prior to the visit. Because both the populations and method of MVS calculation in the MVS derivation and validation studies and the current proposal are identical, 25% is supported by data from our pilot study and is likely to be accurate. To determine the minimal clinically important difference that we should aim to detect, 10 content experts were surveyed. Absolute risk differences ranging from 7.5% to 15% were suggested. We selected a conservative estimate of 10% for the primary outcome (ie, number needed to treat of 10). For the current study, our sample size calculation assumed a 25% event rate in the control group, and we desire to detect an absolute beneficial treatment effect of 10% with 90% power. Using a two-sided type I error ( $\alpha$ ) of 0.05 and the hypothesised proportions yields a required total sample size of 670 patients.<sup>80</sup> Our expected power, if true event rates in our two groups differ from those expected, is presented in [table 2](#). Based on prior work by our group,<sup>18 45 65 81 82</sup> we assumed 10% loss to follow-up (adjustment:  $670/0.90=744$ ), 5% drop out and 3% drop in rate (caregivers who buy a probiotic agent to administer to their child) (adjustment:  $744/(0.92)^2=879$ ). Adjustment for O’Brien-Fleming monitoring boundaries requires a further 2% increase. Thus, the total number randomised (final sample size) is therefore 900. In the fall of 2015, however, 36 patients were potentially exposed to a batch of LGG that was later found to contain inadequate bacterial counts on independent testing. We assumed that approximately 18 of these were exposed and having the same effect as drop-outs. In order to maintain study power under this worst-case scenario, we would have to increase the sample size to 970 patients ( $900/(0.963)^2$ , where 0.963 is 1 minus

the drop-out rate of 18/485=0.037). Based on preliminary surveys, we believe that achieving this sample size is feasible at our sites.

(1) Formal subgroup analyses will be based on (a) age <1year, (b) antibiotic usage, (c) infectious agent (virus, bacteria, parasite or other). Treatment effect will be summarised across subgroups. A subgroup effect will be declared to be significant only if the interaction between treatment and the subgroup factor is significant in an appropriate statistical model (including multivariate regression analyses), using a significance level of <0.05/3=0.017 for each. (2) Duration of vomiting will be analysed only in those subjects reporting ≥3 episodes of vomiting in the 24hours preceding enrolment. (3) Daycare and work absenteeism will only be analysed for those subjects who attend daycare and/or whose caregivers work outside of the home.

### Enrichment design

The above study design and power analysis are based on the assumption of homogeneous treatment effect. We incorporated an enrichment design<sup>83 84</sup> to restore the statistical power if a subpopulation with a substantially low treatment effect is identified. We are particularly interested in two potential subpopulations: participants with <2 days of symptoms and those with ≥2 days of symptoms. Based on our pilot data, each subpopulation accounts for approximately 50% of the total population. The decision for enrolment modification was made at the first interim analysis for efficacy (350 enrolled patients). Specifically, three statistics (based on a normal approximation of binomial distribution or z-statistics) were calculated to compare the primary endpoint between treatment and control groups for subjects in the total population and the two subpopulations, respectively. If the z-statistic from a subpopulation is <0.3 and also smaller than that in the total population, subjects from this subpopulation are no longer to be considered in the subsequent enrolment. All subjects, regardless of symptom duration are to be included in the final analyses. Our simulation studies have showed that such an enrichment design can increase the power considerably when the treatment effects are different across subpopulations, while it will have little impact on power when the treatment effects are similar. Following these analyses performed after 350 patients were enrolled and recommendations by the DSMB, the decision not to modify enrolment was made.

### Frequency of analysis

The DSMB met after 80 (safety at 1 month), 350 and 650 subjects had completed their 1-month follow-up assessments to review enrolment, study procedures, case report form completion, data quality, loss to follow-up, drop-in rate and interim safety and efficacy results. The analyses tested the hypothesis that the probability of developing moderate-to-severe AGE in the probiotic arm is equal to that in the placebo arm. Conservative O’Brien-Fleming monitoring boundaries, implemented using the Lan-DeMets alpha spending function approach, will be used as guidelines for early stopping for efficacy. At each step, the DSMB recommended that the study continue without modifications (table 3).

### Ethics and dissemination

This trial is being conducted under an Investigational New Drug application approved by the FDA (Investigational New Drug application 15371). Institutional review board (IRB) approval has been obtained at all sites. Financial compensation is provided to compensate for parents’ time completing follow-up. This compensation was approved by each site’s IRB. All important modifications will be communicated to the pertinent parties. Data use agreements have been obtained between all sites, and the DCC and Material use agreements have been obtained between all sites and the lead site. The results of the study will be published in peer-reviewed journals. A deidentified public data set will be made available after the completion of all study procedures. The study investigators will have access to the final trial data set. Authorship will be conferred per the International Committee of Medical Journal Editors.

### DISCUSSION

This is the largest RCT of probiotics in children presenting with AGE to an ED to date. We propose to improve outcomes in children affected by AGE by modifying the disease process through biologically plausible mechanisms. Translating this knowledge into a disease-modifying clinical intervention would represent a major change in the approach to this burdensome illness and provide clarity to clinical practice that has been hindered by aggressive marketing in the absence of valid data. Critical elements incorporated into our design that were absent in earlier studies are: (1) evaluating a specific regimen in a large number of participants in a

**Table 3** Interim analyses stopping rules

Analysis	Two-sided p Value	Probability of stopping (80% power) (%)	Probability of stopping (90% power) (%)
First (350 patients)	<0.0007	4.9	8.5
Second (620 patients)	<0.014	40.2	51.2
Final	<0.046	34.9	30.4

geographically diverse network in the USA, (2) using a meaningful and validated outcome in our population, (3) identifying infectious causes, (4) using adaptive randomisation to target specific subgroups and (5) accounting for pre-evaluation administration of probiotics. We attempt to minimise bias by adhering to the 2013 SPIRIT guidelines and the 2010 CONSORT Statement recommendations including the use of 'third-party' assignment.<sup>38</sup> Placebo capsules and active drug are provided by I-Health Inc. The probiotic and placebo capsules and powder are identical in appearance, taste, texture and odour. Participants, families, healthcare providers, data collectors, outcome adjudicators and data analysts are blinded as to intervention arm, thereby preventing bias in outcome assessment. An ITT analysis will be performed to minimise bias associated with poor compliance and non-random loss of participants.<sup>85</sup> Cointerventions (eg, antiemetic administration and intravenous rehydration) and other potential sources of confounding are recorded. Our use of a published validated score as an outcome measure protects against the introduction of bias in the assessment of treatment effects.<sup>86</sup>

Of note, a similar study using a different probiotic product containing *Lactobacillus rhamnosus* and *L. helveticus* (Lacidofil) is being conducted in Canada with funding from the Canadian Institutes of Health Research.<sup>87</sup> This parallel study provides opportunities to enhance our knowledge about the effect of probiotics in children with AGE.

## CONCLUSION

This double-blind, placebo-controlled RCT will quantify the benefits and potential side effects associated with probiotic administration in ambulatory children presenting to the ED with AGE. This will provide the first definitive evidence in the USA for or against using probiotic therapy for this condition and establish the safety of the intervention. The results of this multicentre study will guide the standard of care: if probiotic administration is associated with benefit, it offers a relatively inexpensive and safe to administer treatment to reduce morbidity from AGE. If the trial does not demonstrate probiotic efficacy, healthcare and family and societal resources may be refocused on different interventions.

### Author affiliations

<sup>1</sup>Division of Pediatric Emergency Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

<sup>2</sup>Division of Gastroenterology and Nutrition, Department of Pediatrics, Washington University, School of Medicine, St. Louis, Missouri, USA

<sup>3</sup>Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA

<sup>4</sup>Central Administration, Children's Hospital Minnesota, Minneapolis, Minnesota, USA

<sup>5</sup>Division of Emergency Medicine, Children's National Health System, Department of Pediatrics, The George Washington School of Medicine and Health Sciences, Washington, DC, USA

<sup>6</sup>Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Michigan Wayne State University, Detroit, Michigan, USA

<sup>7</sup>Departments of Emergency Medicine and Pediatrics, University of Michigan, Ann Arbor, Michigan, USA

<sup>8</sup>Department of Emergency Medicine and Pediatrics Providence, Hasbro Children's Hospital and Brown University, Providence, Rhode Island, USA

<sup>9</sup>Division of Emergency Medicine, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

<sup>10</sup>Division of Emergency Medicine, Department of Pediatrics, Columbia University College of Physicians & Surgeons, New York, New York, USA

<sup>11</sup>Division of Emergency Medicine, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

<sup>12</sup>Departments of Emergency Medicine and Pediatrics, University of California, Davis, School of Medicine, Sacramento, California, USA

<sup>13</sup>Department of Emergency Medicine, University of New Mexico, Albuquerque, New Mexico, USA

<sup>14</sup>Department of Surgery, Division of Public Health Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA

<sup>15</sup>Sections of Pediatric Emergency Medicine and Gastroenterology, Department of Pediatrics, Alberta Children's Hospital, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

**Correction notice** This article has been corrected since it first published. The author name 'Casper T Charles' was corrected to 'T Charles Casper'.

**Acknowledgements** We would like to thank the study coordinators Viani Dickey, Deveree Partridge and Melissa Metheny, the DCC staff, the research coordinators and clinicians at all participating sites, as well as the PECARN investigators and subcommittees, without whose support this study could not be conducted. We also thank the members of our DSMB, Dr David Reboussin (chair of the DSMB), Dr Anupam Kharbanda, Dr Oscar Gomez and Dr Robert Shulman.

**Contributors** DS, MHG, PIT and SBF conceptualised the study, obtained funding, obtained an IND for LGG, obtained endorsement by PECARN and wrote the protocol. MJD provided study implementation and regulatory expertise. CTC and FG provided statistical expertise. KJO, PM, THC, SRB, CGR, ECP, AJR, CV and RES provided critical review of the protocol and built enrolment capacity at their sites. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.

**Funding** This work is supported by NICHD grant number R01HD071915. The Pediatric Emergency Care Applied Research Network is supported by the Health Resources and Services Administration, Maternal and Child Health Bureau, Emergency Medical Services for Children Program through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684 and U03MC22685. Dr SF is supported by the Alberta Children's Hospital Foundation Professorship in Child Health and Wellness. Dr PIT is supported by the Washington University Digestive Diseases Research Core Center (P30DK052574). Study sponsors do not have any role in study design, collection management and analysis and interpretation of data nor do they have any role or authority in writing the report nor decision to submit the trial for publication.

**Competing interests** LGG and placebo capsules were provided in kind by i-Health Inc; however, the company did not provide financial contribution to the study or to the investigators, and their employees do not have access to the study data. i-Health Inc personnel do not have any role in study design, collection management and analysis and interpretation of data nor do they have any role or authority in writing the report nor decision to submit the trial for publication.

**Ethics approval** Washington University Institutional Review Board.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

## REFERENCES

- WHO. Diarrhoeal Disease Fact Sheet. 2013 <http://www.who.int/mediacentre/factsheets/fs330/en/>
- Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Updated norovirus outbreak management and disease prevention guidelines. *MMWR Recomm Rep* 2011;60:1–15.
- Leshem E, Moritz RE, Curns AT, et al. Rotavirus vaccines and health care utilization for diarrhea in the United States (2007–2011). *Pediatrics* 2014;134:15–23.
- Payne DC, Vinjé J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. *N Engl J Med Overseas Ed* 2013;368:1121–30.
- Freedman SB, Pasichnyk D, Black KJL, et al. Gastroenteritis Therapies in Developed Countries: Systematic Review and Meta-Analysis. *PLoS One* 2015;10:e0128754.
- Elliott EJ. Acute gastroenteritis in children. *BMJ* 2007;334:35–40.
- Freedman SB, Gouin S, Bhatt M, et al. Prospective assessment of practice pattern Variations in the treatment of pediatric gastroenteritis. *Pediatrics* 2011;127:e287–95.
- Freedman SB, Sivabalasundaram V, Bohn V, et al. The Treatment of Pediatric Gastroenteritis: A Comparative Analysis of Pediatric Emergency Physicians' Practice Patterns. *Academic Emergency Medicine* 2011;18:38–45.
- Reid G. Probiotics: definition, scope and mechanisms of action. *Best Pract Res Clin Gastroenterol* 2016;30:17–25.
- Salminen S, Ouwehand A, Benno Y, et al. Probiotics: how should they be defined? *Trend Food Sci Technol* 1999;10:107–10.
- Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. *Nat Rev Gastroenterol Hepatol* 2010;7:503–14.
- Allen SJ, Martinez EG, Gregorio GV, et al. Probiotics for treating acute infectious diarrhoea. *Cochrane Database Syst Rev* 2010;11:CD003048.
- Szajewska H, Skórka A, Ruszczyński M, et al. Meta-analysis: *Lactobacillus* GG for treating acute gastroenteritis in children - updated analysis of randomised controlled trials. *Aliment Pharmacol Ther* 2013;38:467–76.
- Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of *Saccharomyces boulardii* for acute diarrhea. *Pediatrics* 2014;134:e176–91.
- Schnadower D, Finkelstein Y, Freedman SB. Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries. *Curr Opin Gastroenterol* 2015;31:1–6.
- Coffin SE, Elser J, Marchant C, et al. Impact of acute rotavirus gastroenteritis on pediatric outpatient practices in the United States. *Pediatr Infect Dis J* 2006;25:584–9.
- Klein EJ, Boster DR, Stapp JR, et al. Diarrhea Etiology in a Children's Hospital Emergency Department: A Prospective Cohort Study. *Clinical Infectious Diseases* 2006;43:807–13.
- Schnadower D, Tarr PI, Gorelick MH, et al. Validation of the modified Vesikari score in children with gastroenteritis in 5 US Emergency Departments. *J Pediatr Gastroenterol Nutr* 2013;57:514–9.
- Nixon AF, Cunningham SJ, Cohen HW, et al. The Effect of *Lactobacillus* GG on Acute Diarrheal Illness in the Pediatric Emergency Department. *Pediatr Emerg Care* 2012;28:1048–51.
- D'Souza AL, et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. *BMJ* 2002;324:1361.
- King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. *MMWR Recomm Rep* 2003;52:1–16.
- St L, Klein EJ, Tarr PI, et al. Parental management of childhood diarrhea. *Clin Pediatr* 2009;48:295–303.
- Khanna R, Lakhanpaul M, Burman-Roy S, et al. Diarrhoea and vomiting caused by gastroenteritis in children under 5 years: summary of NICE guidance. *BMJ* 2009;338:b1350.
- Szajewska H, Guarino A, Hojsak I, et al. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. *J Pediatr Gastroenterol Nutr* 2014;58:531–9.
- Katan MB. Why the European Food Safety Authority was right to reject health claims for probiotics. *Benef Microbes* 2012;3:85–9.
- Vero V, Gasbarrini A. The EFSA health claims 'learning experience'. *Int J Food Sci Nutr* 2012;63(sup1):14–16.
- Flynn A. Scientific substantiation of health claims in the EU. *Proc Nutr Soc* 2012;71:120–6.
- Heimbach JT. Health-Benefit Claims for Probiotic Products. *Clinical Infectious Diseases* 2008;46:S122–S124.
- Ma M. US Digestive Health Enzymes, Prebiotics and Probiotics Market (2010–2015). <http://www.marketsandmarkets.com/Market-Reports/digestive-health-225.html>, <http://www.marketsandmarkets.com/Market-Reports/digestive-health-225.html>
- Sanders ME, Shane AL, Merenstein DJ. Advancing probiotic research in humans in the United States: Challenges and strategies. *Gut Microbes* 2016;7:97–100.
- Harrison KL, Farrell RM, Brinich MA, et al. 'Someone should oversee it': patient perspectives on the ethical issues arising with the regulation of probiotics. *Health Expectations* 2015;18:250–61.
- Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic Use. *Emerg Infect Dis* 2010;16:1661–5.
- Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious diarrhoea. *Cochrane Database Syst Rev* 2004;2:CD003048.
- Van Niel CW, Feudtner C, Garrison MM, et al. *Lactobacillus* therapy for acute infectious diarrhea in children: a meta-analysis. *Pediatrics* 2002;109:678–84.
- Soll RF. Probiotics: are we ready for routine use? *Pediatrics* 2010;125:1071–2.
- Vanderhoof JA, Young R. Probiotics in the United States. *Clinical Infectious Diseases* 2008;46:S67–72.
- ClinicalTrials.gov. Clinical Trials Utilizing LGG 2017. <https://clinicaltrials.gov/ct2/results?term=lgg&recr=Open&pg=1>
- Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c869.
- Schulz KF, Altman DG, Consort MD. statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;2010:c332.
- SPIRIT Statement. 2013. <http://www.spirit-statement.org/>
- PECARN. PECARN List of Publications and Abstracts 2017. <http://pecarn.org/publications/index.html>
- World Health Organization. *The treatment of diarrhoea: A manual for physicians and other senior health workers*. 4th revision: WHO Press 2005.
- Brandt CD, Kim HW, Rodriguez WJ, et al. Pediatric viral gastroenteritis during eight years of study. *J Clin Microbiol* 1983;18:71–8.
- Denno DM, Shaikh N, Stapp JR, et al. Diarrhea Etiology in a Pediatric Emergency Department: a case control study Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2012.
- Freedman SB, Eltorkey M, Gorelick M, et al. Evaluation of a gastroenteritis severity score for use in outpatient settings. *Pediatrics* 2010;125:e1278–85.
- Munoz P, Bouza E, Cuenca-Estrella M, et al. *Saccharomyces cerevisiae* fungemia: an emerging infectious disease. *Clin Infect Dis* 2005;40:1625–34.
- Riquelme AJ, Calvo MA, Guzmán AM, et al. *Saccharomyces cerevisiae* fungemia after *Saccharomyces boulardii* treatment in immunocompromised patients. *J Clin Gastroenterol* 2003;36:41–3.
- Shornikova A-V, Isolauri E, Burkanova L, et al. A trial in the Karelian Republic of oral rehydration and *Lactobacillus* GG for treatment of acute diarrhoea. *Acta Paediatr* 1997;86:460–5.
- Guandalini S, Pensabene L, Zikri MA, et al. *Lactobacillus* GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. *J Pediatr Gastroenterol Nutr* 2000;30:54–60.
- Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. *Can Med Assoc J* 2006;175:377–83.
- Szajewska H, Setty M, Mrukowicz J, et al. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. *J Pediatr Gastroenterol Nutr* 2006;42:454–75.
- Nixon AF, Cunningham SJ, Cohen HW, et al. The effect of *Lactobacillus* GG (LGG) on acute diarrheal illness in the pediatric emergency department (PED). *Pediatric Academic Societies* 2010. Annual Meeting [abstract]. Vancouver, Canada.
- Hojsak I, Abdović S, Szajewska H, et al. *Lactobacillus* GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. *Pediatrics* 2010;125:e1171–77.
- Hojsak I, Snovak N, Abdović S, et al. *Lactobacillus* GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. *Clin Nutr* 2010;29:312–6.
- Vandenplas Y, De Hert SG. PROBIOTICAL-study group. Randomised clinical trial: the synbiotic food supplement Probiotal vs. placebo for acute gastroenteritis in children. *Aliment Pharmacol Ther* 2011;34:862–7.
- Caceres PM, Vega S., Cruchet N., et al. Effects of *Lactobacillus rhamnosus* HN001 on acute respiratory infections and intestinal secretory IgA in children. *J Pediatric Infect Dis Soc* 2010;5:353–62.

57. Dotterud CK, Storrø O, Johnsen R, *et al.* Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. *Br J Dermatol* 2010;163:616–23.
58. Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. *Br J Nutr* 2009;101:1722–6.
59. Rose MA, Stieglitz F, Köksal A, *et al.* Efficacy of probiotic *Lactobacillus GG* on allergic sensitization and asthma in infants at risk. *Clin Exp Allergy* 2010;40:1398–405.
60. Sadowska-Krawczenko IK, Polak P, Wietlicka-Piszcz A, *et al.* *Lactobacillus rhamnosus* ATC A07FA for preventing necrotizing enterocolitis in very-low-birth-weight preterm infants: A randomized controlled trial (preliminary results). *Pediatrics Polska* 2012;87:139–45.
61. Szajewska H, Albrecht P, Topczewska-Cabane A. Randomized, double-blind, placebo-controlled trial: effect of *Lactobacillus GG* supplementation on *Helicobacter pylori* eradication rates and side effects during treatment in children. *J Pediatr Gastroenterol Nutr* 2009;48:431–6.
62. Wolvers D, Antoine JM, Myllyluoma E, *et al.* Guidance for Substantiating the Evidence for Beneficial Effects of Probiotics: Prevention and Management of Infections with Probiotics. *J Nutr* 2010.
63. Guandalini S. Probiotics for Children With Diarrhea. *J Clin Gastroenterol* 2008;42(Suppl 2):S53–7.
64. FDA. Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. 2012 <https://www.fda.gov/downloads/Drugs/Guidances/UCM227351.pdf>
65. Freedman SB, Adler M, Seshadri R, *et al.* Oral Ondansetron for Gastroenteritis in a Pediatric Emergency Department. *N Engl J Med Overseas Ed* 2006;354:1698–705.
66. Freedman SB, Willan AR, Boutis K, *et al.* Effect of Dilute Apple Juice and Preferred Fluids vs Electrolyte Maintenance Solution on Treatment Failure Among Children With Mild Gastroenteritis. *JAMA* 2016;315:1966–74.
67. Freedman SB, Parkin PC, Willan AR, *et al.* Rapid versus standard intravenous rehydration in paediatric gastroenteritis: pragmatic blinded randomised clinical trial. *BMJ* 2011;343:d6976.
68. Joensuu J, Koskenniemi E, Pang X-L, *et al.* Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. *The Lancet* 1997;350:1205–9.
69. Givon-Lavi N, Greenberg D, Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. *Vaccine* 2008;26:5798–801.
70. Cicek C, Karatas T, Altuglu I, *et al.* Comparison of ELISA with shell vial cell culture method for the detection of human rotavirus in fecal specimens. *New Microbiol* 2007;30:113–8.
71. Fruhwirth M, Heining U, Ehken B, *et al.* International variation in disease burden of rotavirus gastroenteritis in children with community- and nosocomially acquired infection. *Pediatr Infect Dis J* 2001;20:784–91.
72. Vesikari T, Ruuska T, Delem A, *et al.* Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. *Acta Paediatr* 1991;80:173–80.
73. Binka FN, Anto FK, Oduro AR, *et al.* Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana. *Trop Med Int Health* 2003;8:840–6.
74. Diez-Domingo J, Baldo J-M, Patrzalek M, *et al.* Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis among children aged less than 5 years in six European countries. *Eur J Pediatr* 2011;170:213–22.
75. Leder K, Sinclair M, Forbes A, *et al.* Household clustering of gastroenteritis. *Epidemiol Infect* 2009;137:1705–12.
76. Zelnor JL, King AA, Moe CL, *et al.* How infections propagate after point-source outbreaks: an analysis of secondary norovirus transmission. *Epidemiology* 2010;21:711–8.
77. Holm S. A simple sequentially rejective multiple test procedure. *Scand J Stat* 1979;6:65–70.
78. Van Elteren P. On the combination of independent two-sample tests of Wilcoxon. *Bull Internat Stat Inst* 1960;37:351–61.
79. Nagelkerke N, Fidler V, Bernsen R, *et al.* Estimating treatment effects in randomized clinical trials in the presence of non-compliance. *Stat Med* 2000;19:1849–64.
80. Fleiss J. *Statistical methods for rates and proportions*. 2nd ed. New York: John Wiley & Sons, 1981.
81. Plint AC, Johnson DW, Patel H, *et al.* Epinephrine and dexamethasone in children with bronchiolitis. *N Engl J Med Overseas Ed* 2009;360:2079–89.
82. Corneli HM, Zorc JJ, Mahajan P, *et al.* A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. *N Engl J Med Overseas Ed* 2007;357:331–9.
83. Rosenblum M, van der Laan MJ. Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. *Biometrika* 2011;98:845–60.
84. Meurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? *JAMA: the journal of the American Medical Association* 2012;307:2377–8.
85. Lewis JA, Machin D. Intention to treat – who should use ITT? *Br J Cancer* 1993;68:647–50.
86. Marshall M, *et al.* Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. *Br J Psychiatry* 2000;176:249–52.
87. Freedman SB, Williamson-Urquhart S, Schuh S, *et al.* Impact of emergency department probiotic treatment of pediatric gastroenteritis: study protocol for the PROGUT (Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment) randomized controlled trial. *Trials* 2014;15:170.